期刊文献+

TPSA、F/T及PSAD在前列腺癌诊断中的意义 被引量:4

Role of TPSA, F/T and PSAD in diagnosis of prostate cancer
原文传递
导出
摘要 目的探讨血清中总前列腺特异性抗原(TPSA)、血清游离PSA(FPSA)与TPSA比值(F/T)及PSA密度(PSAD)在前列腺癌诊断中的意义。方法对50例健康体检男性、467例良性前列腺增生症(BPH)及116例前列腺癌患者TPSA、F/T及PSAD值的差异进行分析、比较。结果血清TPSA值前列腺癌组(53.26±33.10)高于BPH组(8.12±9.70)及对照组(1.51±1.17);PSAD值前列腺癌组[(1.59±1.46)ng·ml^-1·cm^-3]高于BPH组[(0.14±0.17)ng·ml^-1·cm^-3]及对照组[(0.08±O.07)ng·ml^-1·cm^-3];而F/T值前列腺癌组(0.22±0.16)低于BPH组(0.27±0.15)及对照组(0.36±0.14),差异均有统计学意义(P值均〈0.01)。PSA处于4~10ng/ml时,前列腺癌组F/T(0.18±0.13)显著低于BPH组(0.27±0.14)(P〈0.05);前列腺癌组PSAD[(0.21±0.07)ng·ml^-1·cm^-3]显著高于BPH组[(0.11±0.06)ng·ml^-1·cm^-3](P〈0.001)。取F/T值0.16、PSAD值0.15ng·ml^-1·cm^-3为临界值时,F/T、PSAD值灵敏度、特异度及阳性预测值分别为81.6%、78.2%、96.1%和53.8%、76.9%、97.9%,诊断效率最高。结论F/T、PSAD是诊断前列腺癌的良好指标,当PSA为4-10ng/ml诊断灰区时,F/T与PSAD对诊断前列腺癌有较好的价值。 Objective To investigate the diagnostic value of serum TPSA, the ratio of free PSA(FPSA) and TPSA(F/T) and PSAD in prostate cancer(PCa). Methods The serum TPSA and PSAD levels and the ratio of F/T of 467 patients with BPH, 116 patients with PCa and 50 healthy men as normal control were determined, analyzed and compared. Results Serum TPSA of PCa (53.26±33.10) were significantly higher than that of BPH (8.12±9.70) (P 〈0.01), and normal control (1.51±1.17) (P 〈0.01); Serum PSAD of PCa [(1.59±l.46) ng'ml-l'cm-3] were significantly higher than that of BPH [(0.14±0.17) ng·ml^-l·cm^-3] (P 〈0.01), and normal control [(0.08±0.07) ng·ml^-1·cm^-3] (P 〈0.01); F/T of PCa (0.22±0.16) was significantly lower than that of BPH (0.27±0.15) and normal control (0.36±0.14) (P 〈0.01). When TPSA was limited specificity at 4 10 ng/ml, F/T of PCa (0.18±0.13) were significantly lower than that of BPH (0.27±0.14), (P 〈0.05), PSAD of Pca [(0.21±0.07) rig. m1^-1. cm^-3] were significantly higher than that of BPH [(0.11±0.06) ng·ml^-1·cm^-3], (P 〈 0.001). When F/T was 0.16, PSAD used 0.15 as the critical value, the sensitivity, specificity of diagnostic value and positive prediction value were 81.6 %, 78.2 %, 96.1% and 53.8 %, 76.9 %, 97.9 %, respectively; And the diagnostic efficiency was the highest. Conclusion F/T and PSAD have valuable role as the diagnose marker of PCa. When PSA level between 4 ng/ml and 10 ng/ml, F/T ratio and PSAD are of significant value to differentiate PCa from BPH patients.
出处 《肿瘤研究与临床》 CAS 2011年第2期111-113,共3页 Cancer Research and Clinic
关键词 前列腺肿瘤 前列腺特异性抗原 前列腺增生 诊断 Prostatic neoplasms Prostate specific antigen Prostate hyperplasia Diagnosis
  • 相关文献

参考文献11

二级参考文献51

  • 1柴克强,凡杰,夏术阶,阮渊,鲁军,唐孝达.PSA及其相关参数在前列腺癌骨转移中的预测作用[J].中国男科学杂志,2006,20(2):22-25. 被引量:9
  • 2Thompson IM, Pauler DK, Goodman P J, et al. Prevalence of prostate cancer among men with a prostatespecific antigen level <or =4.0 ng per milliliter [J]. N Engl J Med, 2004, 350 ( 22 ) : 2239 -2246.
  • 3Stamey TA, Johnstone IM, McNeal JE, et al. Preoperative serum prostate specific antigen levels between 2 and 22 ng/mL correlate poorly with postradical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/mL [J]. J Urol, 2002, 167 (1):103-111.
  • 4Scattoni V, Zlotta A, Montironi R, et al. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature [J]. Eur Urol, 2007,52(5) : 1309-1322.
  • 5Roddam AW, Duffy M J, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/mL: systematic review and meta-analysis [J]. Eur Urol, 2005,48(3) : 386-399.
  • 6Bratslavsky G, Fisher HA, Kaufman RP Jr, et al. PSA-related markers in the detection of prostate cancer and high-grade disease in the contemporary era with extended biopsy [J]. Urol Oncol, 2008,26(2) : 166-170.
  • 7Sokoll LJ, Wang Y, Feng Z, et al.[-2] proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study [J]. J Urol, 2008,180(2) :539-543.
  • 8Fitzpatrick JM, Banu E, Oudard S. Prostate-specific antigen kinetics in localized and advanced prostate cancer [J]. BJU Int, 2009,103(5):57S-587.
  • 9Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 [J]. Nat Genet, 2002,30(2) : 181-184.
  • 10Rokman A, Ikonen T, Seppala EH, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer [J]. Am J Hum Genet, 2002,70(5) : 1299-1304.

共引文献370

同被引文献37

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部